» Articles » PMID: 22655268

Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models

Overview
Journal Front Oncol
Specialty Oncology
Date 2012 Jun 2
PMID 22655268
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Allogeneic stem cell transplantation (allo-SCT) has become an important treatment modality for patients with high-risk acute myeloid leukemia (AML) and is also under investigation for soft tissue sarcomas. The therapeutic success is still limited by minimal residual disease (MRD) status ultimately leading to patients' relapse. Adoptive donor lymphocyte infusions based on MRD status using IL-15-expanded cytokine-induced killer (CIK) cells may prevent relapse without causing graft-versus-host-disease (GvHD). To generate preclinical data we developed mouse models to study anti-leukemic- and anti-tumor-potential of CIK cells in vivo. Immunodeficient mice (NOD/SCID/IL-2Rγc(-), NSG) were injected intravenously with human leukemic cell lines THP-1, SH-2 and with human rhabdomyosarcoma (RMS) cell lines RH41 and RH30 at minimal doses required for leukemia or tumor engraftment. Mice transplanted with THP-1 or RH41 cells were randomly assigned for analysis of CIK cell treatment. Organs of mice were analyzed by flow cytometry as well as quantitative polymerase chain reaction for engraftment of malignant cells and CIK cells. Potential of CIK cells to induce GvHD was determined by histological analysis. Tissues of the highest degree of THP-1 cell expansion included bone marrow followed by liver, lung, spleen, peripheral blood (PB), and brain. RH30 and RH41 engraftment mainly took place in liver and lung, but was also detectable in spleen and PB. In spite of delayed CIK cell expansion compared with malignant cells, CIK cells injected at equal amounts were sufficient for significant reduction of RH41 cells, whereas against fast-expanding THP-1 cells 250 times more CIK than THP-1 cells were needed to achieve comparable results. Our preclinical in vivo mouse models showed a reliable 100% engraftment of malignant cells which is essential for analysis of anti-cancer therapy. Furthermore our data demonstrated that IL-15-activated CIK cells have potent cytotoxic capacity against AML and RMS cells without causing GvHD.

Citing Articles

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.

Moser L, Heim C, Koschade S, Wendel P, Bozkurt S, Harenkamp S Front Immunol. 2025; 16:1485817.

PMID: 39963129 PMC: 11831232. DOI: 10.3389/fimmu.2025.1485817.


Natural killer cell-based immunotherapy for acute myeloid leukemia.

Xu J, Niu T J Hematol Oncol. 2020; 13(1):167.

PMID: 33287858 PMC: 7720594. DOI: 10.1186/s13045-020-00996-x.


ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.

Merker M, Wagner J, Kreyenberg H, Heim C, Moser L, Wels W Front Immunol. 2020; 11:581468.

PMID: 33193388 PMC: 7641627. DOI: 10.3389/fimmu.2020.581468.


CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.

Leuci V, Donini C, Grignani G, Rotolo R, Mesiano G, Fiorino E Clin Cancer Res. 2020; 26(23):6321-6334.

PMID: 32900797 PMC: 7710537. DOI: 10.1158/1078-0432.CCR-20-0357.


Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.

Sabry M, Lowdell M Stem Cells Transl Med. 2020; 9(9):974-984.

PMID: 32416056 PMC: 7445022. DOI: 10.1002/sctm.19-0423.


References
1.
Seriu T, Stolz F, DAniello E, Gameiro P, Pisa P, Gonzalez M . Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION:.... Leukemia. 1999; 13(1):110-8. DOI: 10.1038/sj.leu.2401245. View

2.
Scheffold C, Kornacker M, Scheffold Y, Contag C, Negrin R . Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. Cancer Res. 2002; 62(20):5785-91. View

3.
Nakamura Y, Ito M, Yamamoto T, Yan X, Yagasaki H, Kamachi Y . Engraftment of NOD/SCID/gammac(null) mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2005; 130(1):51-7. DOI: 10.1111/j.1365-2141.2005.05578.x. View

4.
Schmidt-Wolf I, Negrin R, Kiem H, Blume K, Weissman I . Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991; 174(1):139-49. PMC: 2118875. DOI: 10.1084/jem.174.1.139. View

5.
Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P . Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol. 2004; 22(9):1696-705. DOI: 10.1200/JCO.2004.05.198. View